ArticleBlood advances2017
The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Second primary malignancy in multiple myeloma: does a prior malignancy matter?Haematologica · 2026Article
- Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population-Based Cohort Study.Cancer medicine · 2025Article
- Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation.Transplantation and cellular therapy · 2025Article
- Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.Frontiers in immunology · 2025Article
- Article
- Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.Blood cancer journal · 2022Article
- Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.European journal of haematology · 2021Article
- Article
- Treatment and disease-related complications in multiple myeloma: Implications for survivorship.American journal of hematology · 2020Review
- Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis.Annals of hematology · 2020Article
- Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment.British journal of haematology · 2020Article
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
- Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report.Open medicine (Warsaw, Poland) · 2020Article
- Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.JAMA oncology · 2019Article
- Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.Leukemia · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
Abstract
In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent malignancy development in multiple myeloma (MM) patients. Second, we hypothesize that survival after MM is influenced by a prior malignancy. All patients diagnosed with MM from 1 January 1973 to 31 December 2010 were identified from the Swedish Cancer Register. Cox regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) where prior malignancy was compared in MM patients who developed a subsequent malignancy and MM patients who did not. In another Cox regression model, survival was compared in MM patients with and without a prior malignancy diagnosis. A total of 19 791 patients were diagnosed with MM. Patients with a prior malignancy diagnosis had a significantly increased risk of developing a subsequent malignancy compared with MM patients without (HR 1.42, 95% CI 1.23-1.65,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.